Skip to Content

Rule

Schedules of Controlled Substances: Exempt Anabolic Steroid Products

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 53677

AGENCY:

Drug Enforcement Administration (DEA), Department of Justice.

ACTION:

Final rule; reinstatement of exemptions.

SUMMARY:

The DEA is withdrawing the suspension of the interim rule published on June 13, 2003 and reinstating the order published on January 15, 2003 designating two pharmaceutical preparations as exempt anabolic steroid products under the Controlled Substances Act (CSA). The current action is being taken after reconsidering the application for exemption in light of the comments and objections filed and other relevant information. This action is part of the ongoing implementation of the Anabolic Steroids Control Act (ASCA) of 1990.

EFFECTIVE DATE:

September 12, 2003.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Frank Sapienza, Chief, Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Background

The ASCA of 1990 (Title XIX of Public Law 101-647) placed anabolic steroids into Schedule III of the CSA (21 U.S.C. 812). Section 1903 of the ASCA provides that the Attorney General may exempt products which contain anabolic steroids from all or any part of the CSA (21 U.S.C. 801 et seq.) if the products have no significant potential for abuse. The authority to exempt these products was delegated from the Attorney General to the Administrator of the Drug Enforcement Administration (28 CFR 0.1009b), who, in turn, redelegated this authority to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (28 CFR appendix to subpart R, Section 7, paragraph (g)). The procedure for implementing this section of the ASCA is found in § 1308.33 of Title 21 of the Code of Federal Regulations.

In conformance with § 1308.33 of Title 21 of the Code of Federal Regulations, an application was received from Syntho Pharmaceuticals, Inc. to exempt two of their anabolic steroid products, Syntest H.S. and Syntest D.S. This application was forwarded to the Assistant Secretary for Health, Department of Health and Human Services (HHS) for her evaluation. Upon the recommendation of HHS and other relevant information, the DEA published an interim rule and request for comments (68 FR 1964, January 15, 2003) in which the Deputy Assistant Administrator ordered the products to be added to the list of exempt anabolic steroids.

DEA received two comments from interested persons that raised issues regarding findings of fact or conclusions of law upon which this order was based. As set forth in 21 CFR 1308.33(d), the Deputy Assistant Administrator immediately suspended the effectiveness of this order until she reconsidered the application in light of the comments and objections filed.

Reinstatement of Order To Add Anabolic Steroid Products to the List of Products Exempted From Application of the CSA

A preparation containing an anabolic steroid may be exempted from the requirements of the CSA if it has no significant potential for abuse. Accordingly, the DEA is responding only to those aspects of the comments received that raise the issue of abuse potential of Syntest H.S. and Syntest D.S. One commenter made reference to the abuse of anabolic steroids, in general. Although the abuse of anabolic steroids is of great concern to the DEA, no information was presented to alter the initial findings that the products do not possess a significant potential for abuse. The second commenter alleged that Syntho Pharmaceutical, Inc. distributed the products as exempt preparations prior to the exemptions being granted; however, there is no evidence of any abuse or significant potential for abuse of the products as a result of this activity by the company. Thus, after a thorough review and investigation of the two comments DEA received, and all other relevant information, the DEA found no indication that there is a significant potential for abuse of either Syntest H.S. or Syntest D.S. Therefore, in compliance with 21 CFR 1308.33(d), the Deputy Assistant Administrator reinstates her original order to add the products to the list of exempt anabolic steroids.

Start Signature

Dated: September 8, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control.

End Signature End Supplemental Information

[FR Doc. 03-23287 Filed 9-11-03; 8:45 am]

BILLING CODE 4410-09-P